These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 19410458)

  • 21. Discovery of benzisoxazoles as potent inhibitors of chaperone heat shock protein 90.
    Gopalsamy A; Shi M; Golas J; Vogan E; Jacob J; Johnson M; Lee F; Nilakantan R; Petersen R; Svenson K; Chopra R; Tam MS; Wen Y; Ellingboe J; Arndt K; Boschelli F
    J Med Chem; 2008 Feb; 51(3):373-5. PubMed ID: 18197612
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design, synthesis, and biological evaluation of novel deguelin-based heat shock protein 90 (HSP90) inhibitors targeting proliferation and angiogenesis.
    Chang DJ; An H; Kim KS; Kim HH; Jung J; Lee JM; Kim NJ; Han YT; Yun H; Lee S; Lee G; Lee S; Lee JS; Cha JH; Park JH; Park JW; Lee SC; Kim SG; Kim JH; Lee HY; Kim KW; Suh YG
    J Med Chem; 2012 Dec; 55(24):10863-84. PubMed ID: 23186287
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.
    Engel D; Nudelman A; Tarasenko N; Levovich I; Makarovsky I; Sochotnikov S; Tarasenko I; Rephaeli A
    J Med Chem; 2008 Jan; 51(2):314-23. PubMed ID: 18163551
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Isoxazolo(aza)naphthoquinones: a new class of cytotoxic Hsp90 inhibitors.
    Bargiotti A; Musso L; Dallavalle S; Merlini L; Gallo G; Ciacci A; Giannini G; Cabri W; Penco S; Vesci L; Castorina M; Milazzo FM; Cervoni ML; Barbarino M; Pisano C; Giommarelli C; Zuco V; De Cesare M; Zunino F
    Eur J Med Chem; 2012 Jul; 53():64-75. PubMed ID: 22538015
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90.
    Llauger L; He H; Kim J; Aguirre J; Rosen N; Peters U; Davies P; Chiosis G
    J Med Chem; 2005 Apr; 48(8):2892-905. PubMed ID: 15828828
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification and optimization of novel 6-acylamino-2-aminoquinolines as potent Hsp90 C-terminal inhibitors.
    Jiang F; Guo AP; Xu JC; Wang HJ; Mo XF; You QD; Xu XL
    Eur J Med Chem; 2017 Dec; 141():1-14. PubMed ID: 29028527
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis, bioconversion, pharmacokinetic and pharmacodynamic evaluation of N-isopropyl-oxy-carbonyloxymethyl prodrugs of CZh-226, a potent and selective PAK4 inhibitor.
    Guo J; Wang T; Wu T; Zhang K; Yin W; Zhu M; Pang Y; Hao C; He Z; Cheng M; Liu Y; Zheng J; Gu J; Zhao D
    Eur J Med Chem; 2020 Jan; 186():111878. PubMed ID: 31757524
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents.
    Bagatell R; Paine-Murrieta GD; Taylor CW; Pulcini EJ; Akinaga S; Benjamin IJ; Whitesell L
    Clin Cancer Res; 2000 Aug; 6(8):3312-8. PubMed ID: 10955818
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radanamycin, a macrocyclic chimera of radicicol and geldanamycin.
    Wang M; Shen G; Blagg BS
    Bioorg Med Chem Lett; 2006 May; 16(9):2459-62. PubMed ID: 16464590
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimization of potent, selective, and orally bioavailable pyrrolodinopyrimidine-containing inhibitors of heat shock protein 90. Identification of development candidate 2-amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide.
    Zehnder L; Bennett M; Meng J; Huang B; Ninkovic S; Wang F; Braganza J; Tatlock J; Jewell T; Zhou JZ; Burke B; Wang J; Maegley K; Mehta PP; Yin MJ; Gajiwala KS; Hickey MJ; Yamazaki S; Smith E; Kang P; Sistla A; Dovalsantos E; Gehring MR; Kania R; Wythes M; Kung PP
    J Med Chem; 2011 May; 54(9):3368-85. PubMed ID: 21438541
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chiral resolution and pharmacological characterization of the enantiomers of the Hsp90 inhibitor 2-amino-7-[4-fluoro-2-(3-pyridyl)phenyl]-4-methyl-7,8-dihydro-6H-quinazolin-5-one oxime.
    Amici R; Bigogno C; Boggio R; Colombo A; Courtney SM; Dal Zuffo R; Dondio G; Fusar F; Gagliardi S; Minucci S; Molteni M; Montalbetti CA; Mortoni A; Varasi M; Vultaggio S; Mercurio C
    ChemMedChem; 2014 Jul; 9(7):1574-85. PubMed ID: 24753447
    [TBL] [Abstract][Full Text] [Related]  

  • 32. EB1627: a soluble prodrug of the potent anticancer cyanoguanidine CHS828.
    Binderup E; Björkling F; Hjarnaa PV; Latini S; Baltzer B; Carlsen M; Binderup L
    Bioorg Med Chem Lett; 2005 May; 15(10):2491-4. PubMed ID: 15863303
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis and evaluation of coumermycin A1 analogues that inhibit the Hsp90 protein folding machinery.
    Burlison JA; Blagg BS
    Org Lett; 2006 Oct; 8(21):4855-8. PubMed ID: 17020320
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design and synthesis of 2-amino-6-(1H,3H-benzo[de]isochromen-6-yl)-1,3,5-triazines as novel Hsp90 inhibitors.
    Suda A; Kawasaki K; Komiyama S; Isshiki Y; Yoon DO; Kim SJ; Na YJ; Hasegawa K; Fukami TA; Sato S; Miura T; Ono N; Yamazaki T; Saitoh R; Shimma N; Shiratori Y; Tsukuda T
    Bioorg Med Chem; 2014 Jan; 22(2):892-905. PubMed ID: 24369839
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis and Biological Evaluation of Novobiocin Core Analogues as Hsp90 Inhibitors.
    Byrd KM; Subramanian C; Sanchez J; Motiwala HF; Liu W; Cohen MS; Holzbeierlein J; Blagg BS
    Chemistry; 2016 May; 22(20):6921-31. PubMed ID: 27037933
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90.
    Ge J; Normant E; Porter JR; Ali JA; Dembski MS; Gao Y; Georges AT; Grenier L; Pak RH; Patterson J; Sydor JR; Tibbitts TT; Tong JK; Adams J; Palombella VJ
    J Med Chem; 2006 Jul; 49(15):4606-15. PubMed ID: 16854066
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis of Hsp90 inhibitor dimers as potential antitumor agents.
    Muranaka K; Sano A; Ichikawa S; Matsuda A
    Bioorg Med Chem; 2008 Jun; 16(11):5862-70. PubMed ID: 18487051
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New Taxol (paclitaxel) prodrugs designed for ADEPT and PMT strategies in cancer chemotherapy.
    Alaoui AE; Saha N; Schmidt F; Monneret C; Florent JC
    Bioorg Med Chem; 2006 Jul; 14(14):5012-9. PubMed ID: 16554162
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis and antitumor efficacy of a β-glucuronidase-responsive albumin-binding prodrug of doxorubicin.
    Legigan T; Clarhaut J; Renoux B; Tranoy-Opalinski I; Monvoisin A; Berjeaud JM; Guilhot F; Papot S
    J Med Chem; 2012 May; 55(9):4516-20. PubMed ID: 22515366
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HSP90 Inhibitor-SN-38 Conjugate Strategy for Targeted Delivery of Topoisomerase I Inhibitor to Tumors.
    Proia DA; Smith DL; Zhang J; Jimenez JP; Sang J; Ogawa LS; Sequeira M; Acquaviva J; He S; Zhang C; Khazak V; Astsaturov I; Inoue T; Tatsuta N; Osman S; Bates RC; Chimmanamada D; Ying W
    Mol Cancer Ther; 2015 Nov; 14(11):2422-32. PubMed ID: 26271675
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.